BIOCON vs TORNTPHARM
Side-by-side comparison of Biocon Ltd. and Torrent Pharmaceuticals Ltd.. Descriptive only — not investment advice.
Biocon Ltd.
Pharma
Quality Score: 45/100
Torrent Pharmaceuticals Ltd.
Pharma
Quality Score: 63/100
At a glance
| Metric | BIOCON | TORNTPHARM |
|---|---|---|
| Quality Score | 45/100 | 63/100 |
| P/E (trailing) | 151.5 | 82.1 |
| Forward P/E | 36.5 | 53.7 |
| ROE | +1.1% | — |
| Profit margin | +2.3% | +13.9% |
| Debt-to-equity | 42.15 | 85.45 |
| Dividend yield | +0.12% | +0.78% |
| 1Y price return | +9.9% | +35.7% |
| From 52w high | -4.9% | -4.2% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.35 | 1.72 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
Biocon trades at a trailing PE of 151.5x against a trailing ROE of 1.15% and profit margin of 2.28%, while forward PE compresses to 36.5x on consensus earnings estimates. Price technicals show the stock above both its 50-day (₹422.42) and 200-day (₹390.60) moving averages, up 9.91% over one year and 15.64% over three months, with recent news dominated by the July 2026 clearance of Mylan's block-deal stake sale and a Health Canada approval for its Yesintek biosimilar.
Torrent Pharmaceuticals trades at ₹4,872.10, up 35.67% over the past year and currently above both its 50-day (₹4,663.97) and 200-day (₹4,154.10) moving averages, sitting 4.2% below its 52-week high. Q1 FY27 revenue rose 55% YoY to ₹4,921 crore following completion of the amalgamation with J.B. Chemicals, though the stock's trailing PE of 82.15x is the highest among six reported pharma peers and 5-year earnings growth (-8.2%) has lagged 5-year revenue growth (+54.8%).
Pros
- ✓Received Health Canada approval for its Yesintek autoinjector biosimilar (July 30, 2026), one of the on-target positive items in recent news flow.
- ✓Trades above both the 50-day (₹422.42) and 200-day (₹390.60) moving averages, up 9.91% over the trailing year and 15.64% over three months, sitting only 4.88% below its 52-week high.
- ✓Debt-to-equity of 0.42x with a flat debt trend, and free cash flow positive in 4 of the last 5 years.
- ✓Forward PE of 36.5x is well below the trailing PE of 151.5x, indicating consensus estimates embed a material improvement in near-term earnings versus the trailing base.
- ✓Price sits above both the 50-DMA and 200-DMA, with a 35.67% gain over the trailing 12 months and a 14.19% gain over the trailing 3 months.
- ✓ROE exceeded 15% in 4 of the past 5 tracked years and free cash flow was positive in 4 of the past 5 tracked years, with an overall consistency score of 77.
- ✓Q1 FY27 revenue rose 55% YoY to ₹4,921 crore and EBITDA rose 61%, alongside completion of the amalgamation with J.B. Chemicals and the July 21, 2026 allotment of 4.19 crore shares.
- ✓Mean analyst rating of 1.72 across 29 analysts (1–5 scale, lower = more constructive); 5 of the 7 tracked headlines in the sample window were classified positive with none negative.
Cons
- ✗ROE has not exceeded 15% in any year of the observed persistence window, trailing profit margin is 2.28%, and 5-year earnings growth is -72.5%, indicating the core business has not consistently generated returns above its cost of capital.
- ✗Trailing PE of 151.5x is the highest among 6 profiled pharma-sector peers — more than double the next-highest, MAXHEALTH at 74.6x — while its quality score of 15/100 ranks 5th of 6 in the same peer set.
- ✗Mean analyst rating of 2.35 across 19 analysts (1-5 scale, lower = more constructive) sits in the mid-range rather than at the more constructive end of the scale.
- ✗Consistency score of 35/100 and 5-year revenue growth of just 2.3% point to a limited track record of durable growth alongside the profitability gaps noted above.
- ✗Debt-to-equity of 0.85x is elevated for the pharma sector and the persistence data flags the debt trend as rising.
- ✗5-year earnings growth of -8.2% trails 5-year revenue growth of +54.8%; current profit margin is 13.87%.
- ✗Trailing PE of 82.15x is the highest of six reported sector peers (ranked 6 of 6 on valuation), while the quality score of 30 ranks only 4th of 6 among the same peer set.
- ✗The news sample is small (7 headlines) and appears to include an unrelated Coal India story, which limits confidence in the raw sentiment tally for the window.
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.